litlas
ログインアカウント作成

Philippe Rousselot

1990–2025 年に発表

127
論文数
26,995
被引用数
76
h 指数
122
i10 指数

被引用数

Philippe Rousselot の年別被引用数1979 年: 被引用 8 件1991 年: 被引用 1 件1992 年: 被引用 5 件1993 年: 被引用 3 件1994 年: 被引用 3 件1995 年: 被引用 5 件1996 年: 被引用 9 件1997 年: 被引用 12 件1998 年: 被引用 12 件1999 年: 被引用 16 件2000 年: 被引用 14 件2001 年: 被引用 23 件2002 年: 被引用 30 件2003 年: 被引用 70 件2004 年: 被引用 95 件2005 年: 被引用 81 件2006 年: 被引用 101 件2007 年: 被引用 186 件2008 年: 被引用 203 件2009 年: 被引用 190 件2010 年: 被引用 188 件2011 年: 被引用 173 件2012 年: 被引用 181 件2013 年: 被引用 177 件2014 年: 被引用 191 件2015 年: 被引用 219 件2016 年: 被引用 233 件2017 年: 被引用 216 件2018 年: 被引用 215 件2019 年: 被引用 774 件2020 年: 被引用 796 件2021 年: 被引用 665 件2022 年: 被引用 464 件2023 年: 被引用 307 件2024 年: 被引用 695 件2025 年: 被引用 316 件2026 年: 被引用 2 件1980〜1990 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,093 件、この内訳の 25.7%フランス: 引用元論文 636 件、この内訳の 7.8%ドイツ: 引用元論文 612 件、この内訳の 7.5%イタリア: 引用元論文 581 件、この内訳の 7.1%イギリス: 引用元論文 539 件、この内訳の 6.6%中国: 引用元論文 459 件、この内訳の 5.6%カナダ: 引用元論文 241 件、この内訳の 3%オーストラリア: 引用元論文 240 件、この内訳の 3%スペイン: 引用元論文 219 件、この内訳の 2.7%スイス: 引用元論文 217 件、この内訳の 2.7%オランダ: 引用元論文 201 件、この内訳の 2.5%日本: 引用元論文 190 件、この内訳の 2.3%
0%25.7%その他 23.5%

機関

分野

  • Medicine75.8%
  • Biochemistry, Genetics and Molecular Biology16.6%
  • Immunology and Microbiology3.8%
  • Computer Science0.6%
  • Chemistry0.5%
  • Materials Science0.4%
  • その他2.3%

トピック

  • Chronic Myeloid Leukemia Treatments14%
  • Acute Myeloid Leukemia Research9%
  • Chronic Lymphocytic Leukemia Research7.4%
  • Acute Lymphoblastic Leukemia research6.1%
  • Eosinophilic Disorders and Syndromes5.8%
  • CAR-T cell therapy research2.4%
  • その他55.3%

共著者

全論文

検索で開く
  1. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

    著者: Sylvie Castaigné, Cécile Pautas, Christine Terré, Emmanuel Raffoux, Dominique Bordessoule, Jean Bastié, Ollivier Legrand, Xavier Thomas, Pascal Turlure, Oumédaly Reman, Thierry de Revel, Lauris Gastaud, Noémie de Gunzburg, Nathalie Contentin, Estelle Henry, Jean‐Pierre Marolleau, Ahmad Aljijakli, Philippe Rousselot, Pierre Fenaux, Claude Preudhomme, Sylvie Chevret, Hervé Dombret - The Lancet 2012 被引用: 995

  2. Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

    著者: Brian Druker, François Guilhot, Stephen G. O’Brien, Insa Gathmann, Hagop M. Kantarjian, Norbert Gattermann, Michael W. Deininger, Richard T. Silver, John M. Goldman, Richard M. Stone, Francisco Cervantes, Andreas Hochhaus, Bayard L. Powell, Janice Gabrilove, Philippe Rousselot, Josy Reiffers, Jan J. Cornelissen, Timothy P. Hughes, Hermine Agis, Thomas Fischer, Gregor Verhoef, John D. Shepherd, Giuseppe Saglio, Aloïs Gratwohl, Johan Lanng Nielsen, Jerald P. Radich, Bengt Simonsson, Kerry Taylor, Michele Baccarani, Charlene So, Laurie Letvak, Richard A. Larson - New England Journal of Medicine 2006 被引用: 3,481

  3. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

    著者: François‐Xavier Mahon, Delphine Réa, Joëlle Guilhot, François Guilhot, Françoise Huguet, Franck E. Nicolini, Laurence Legros, Aude Charbonnier, Agnès Guerci, Bruno Varet, Gabriel Étienne, Josy Reiffers, Philippe Rousselot - The Lancet Oncology 2010 被引用: 1,538

  4. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial

    著者: Jörge E. Cortes, Jane F. Apperley, Elza Lomaia, Beatriz Moiraghi, Maria Undurraga Sutton, Carolina Pavlovsky, Charles Chuah, Tomasz Sacha, Jeffrey H. Lipton, Charles A. Schiffer, James McCloskey, Andreas Hochhaus, Philippe Rousselot, Gianantonio Rosti, Hugues de Lavallade, Anna Turkina, Christine Rojas, Christopher Arthur, Lori J. Maness, Moshe Talpaz, Michael J. Mauro, Tracey Hall, Vickie Lu, Shouryadeep Srivastava, Michael Deininger - Blood 2021 被引用: 193

  5. Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

    著者: Stephen G. O’Brien, François Guilhot, Richard A. Larson, Insa Gathmann, Michele Baccarani, Francisco Cervantes, Jan J. Cornelissen, Thomas Fischer, Andreas Hochhaus, Timothy P. Hughes, Klaus Lechner, Johan Lanng Nielsen, Philippe Rousselot, Josy Reiffers, Giuseppe Saglio, John D. Shepherd, Bengt Simonsson, Aloïs Gratwohl, John M. Goldman, Hagop M. Kantarjian, Kerry Taylor, Gregor Verhoef, Ann E. Bolton, Renaud Capdeville, Brian Druker - New England Journal of Medicine 2003 被引用: 3,565

  6. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

    著者: Susanne Saußele, Johan Richter, Joëlle Guilhot, Franz Gruber, Henrik Hjorth-Hansen, António Almeida, Jeroen J. W. M. Janssen, Jiřı́ Mayer, Perttu Koskenvesa, Panayiotis Panayiotidis, Ulla Olsson‐Strömberg, Joaquín Martínez‐López, Philippe Rousselot, Hanne Vestergaard, Hans Ehrencrona, Veli Kairisto, Kateřina Machová Poláková, Martin C. Müller, Satu Mustjoki, Marc Berger, Alice Fabarius, Wolf‐Karsten Hofmann, Andreas Hochhaus, Markus Pfirrmann, François‐Xavier Mahon, Gert J. Ossenkoppele, Maria Pagoni, Stina Söderlund, Martine Escoffre‐Barbe, Gabriel Étienne, Jolanta Dengler, Françoise Huguet, Nikolas von Bubnoff, Hana Klamová, Edgar Faber, François Guilhot, Kourosh Lotfi, Delphine Réa, Tim H. Brümmendorf, G.E. de Greef, Leif Stenke, Franck E. Nicolini, Laurence Legros, Andreas Burchert, J Voglová, Aude Charbonnier, Emmanuel Gyan, Volker Kunzmann, Peter E. Westerweel - The Lancet Oncology 2018 被引用: 611

  7. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial

    著者: Tim H. Brümmendorf, Jörge E. Cortes, Dragana Milojković, Carlo Gambacorti‐Passerini, Richard E. Clark, Philipp le Coutre, Valentín García‐Gutiérrez, Charles Chuah, Vamsi Kota, Jeffrey H. Lipton, Philippe Rousselot, Michael J. Mauro, Andreas Hochhaus, Rafael Hurtado Monroy, Eric Leip, Simon Purcell, Anne Yver, Andrea Viqueira, Michael W. Deininger, BFORE study investigators - Leukemia 2022 被引用: 141

  8. Ponatinib vs Imatinib in Frontline Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

    著者: Elias Jabbour, Hagop M. Kantarjian, Ibrahim Aldoss, Pau Montesinos, Jessica Leonard, David Gómez‐Almaguer, Maria R. Baer, Carlo Gambacorti‐Passerini, James McCloskey, Yosuke Minami, Cristina Papayannidis, Vanderson Rocha, Philippe Rousselot, Pankit Vachhani, Eunice S. Wang, Bingxia Wang, Meliessa Hennessy, Alexander Vorog, Niti Patel, Tammie C. Yeh, Josep‐María Ribera - JAMA 2024 被引用: 114

  9. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

    著者: Michele Baccarani, Michael Deininger, Gianantonio Rosti, Andreas Hochhaus, Simona Soverini, Jane F. Apperley, Francisco Cervantes, Richard E. Clark, Jörge E. Cortes, François Guilhot, Henrik Hjorth‐Hansen, Timothy P. Hughes, Hagop M. Kantarjian, Dong‐Wook Kim, Richard A. Larson, Jeffrey H. Lipton, François-Xavier Mahon, Giovanni Martinelli, Jiřı́ Mayer, Martin Müller, Dietger Niederwieser, Fabrizio Pane, Jerald P. Radich, Philippe Rousselot, Giuseppe Saglio, Susanne Saußele, Charles A. Schiffer, Richard T. Silver, Bengt Simonsson, Juan-Luis Steegmann, John M. Goldman, Rüdiger Hehlmann - Blood 2013 被引用: 1,989

  10. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL

    著者: Philippe Rousselot, marie Magdelaine Coude, Nicola Gökbuget, Carlo Gambacorti‐Passerini, Sandrine Hayette, Jean‐Michel Cayuela, Françoise Huguet, Thibaut Leguay, Patrice Chevallier, Célia Salanoubat, Caroline Bonmati, Magda Alexis, Mathilde Hunault, Sylvie Glaisner, Philippe Agapé, Christian Berthou, Éric Jourdan, José Fernandes, Laurent Sutton, Anne Banos, Oumédaly Reman, Bruno Lioure, Xavier Thomas, Norbert Ifrah, Mårina Lafage‐Pochitaloff, Anne Bornand, Laure Morisset, Valérie Robin, Heike Pfeifer, André Delannoy, Josep‐María Ribera, Renato Bassan, Marc Delord, Dieter Hoelzer, Hervé Dombret, Oliver G. Ottmann - Blood 2016 被引用: 326

  11. Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia

    著者: Gabriel Étienne, Joëlle Guilhot, Delphine Réa, Françoise Rigal‐Huguet, Franck E. Nicolini, Aude Charbonnier, Agnès Guerci‐Bresler, Laurence Legros, Bruno Varet, Martine Gardembas, Viviane Dubruille, Michel Tulliez, Marie‐Pierre Noël, Jean‐Christophe Ianotto, Bruno Villemagne, Martin Carré, François Guilhot, Philippe Rousselot, François‐Xavier Mahon - Journal of Clinical Oncology 2016 被引用: 494

  12. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia

    著者: Yves Chalandon, Xavier Thomas, Sandrine Hayette, Jean‐Michel Cayuela, Claire Abbal, Françoise Huguet, Emmanuel Raffoux, Thibaut Leguay, Philippe Rousselot, Stéphane Leprêtre, Martine Escoffre‐Barbe, Sébastien Maury, Céline Berthon, Emmanuelle Tavernier, Jean‐François Lambert, Mårina Lafage‐Pochitaloff, Véronique Lhéritier, Sylvie Chevret, Norbert Ifrah, Hervé Dombret - Blood 2015 被引用: 374

  13. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

    著者: Robert J. Kreitman, Claire Dearden, Pier Luigi Zinzani, Julio Delgado, Lionel Karlin, Tadeusz Robak, Douglas E. Gladstone, Philipp le Coutre, Sascha Dietrich, Mirjana Gotić, Loree Larratt, Fritz Offner, Gary J. Schiller, Ronan Swords, Larry Bacon, Monica Bocchia, Krimo Bouabdallah, Dimitri Breems, Agostino Cortelezzi, Shira Dinner, Michael Doubek, Bjørn Tore Gjertsen, Marco Gobbi, Andrzej Hellmann, Stéphane Leprêtre, Frédéric Maloisel, Farhad Ravandi, Philippe Rousselot, Mathias Rummel, Tanya Siddiqi, Tamar Tadmor, Xavier Troussard, Cecilia Arana Yi, Giuseppe Saglio, Gail J. Roboz, Kemal Balic, Nathan Standifer, Peng He, Shannon Marshall, Wyndham H. Wilson, Ira Pastan, Nai-Shun Yao, Francis J. Giles - Leukemia 2018 被引用: 247

  14. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial

    著者: Jörge E. Cortes, Alexander E. Perl, Hartmut Döhner, Hagop M. Kantarjian, Giovanni Martinelli, Tibor Kovacsovics, Philippe Rousselot, Björn Steffen, Hervé Dombret, Elihu H. Estey, Stephen A. Strickland, Jessica K. Altman, Claudia D. Baldus, Alan K. Burnett, Alwin Krämer, Nigel H. Russell, Neil P. Shah, Catherine C. Smith, Eunice S. Wang, Norbert Ifrah, Guy Gammon, Denise Trone, Deborah Lazzaretto, Mark J. Levis - The Lancet Oncology 2018 被引用: 264

  15. Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension

    著者: Christophe Guignabert, Carole Phan, Andrei Seferian, Alice Huertas, Ly Tu, Raphaël Thuillet, C.H. Sattler, Morane Le Hiress, Yuichi Tamura, Etienne‐Marie Jutant, Marie‐Camille Chaumais, Stéphane Bouchet, Benjamin Manéglier, Mathiéu Molimard, Philippe Rousselot, Olivier Sitbon, Gérald Simonneau, David Montani, Marc Humbert - Journal of Clinical Investigation 2016 被引用: 273

  16. Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial

    著者: Françoise Huguet, Sylvie Chevret, Thibaut Leguay, Xavier Thomas, Nicolas Boissel, Martine Escoffre‐Barbe, Patrice Chevallier, Mathilde Hunault, Norbert Vey, Caroline Bonmati, Stéphane Leprêtre, Jean‐Pierre Marolleau, Thomas Pabst, Philippe Rousselot, Agnès Buzyn, Jean‐Yves Cahn, Véronique Lhéritier, Marie C. Béné, Vahid Asnafi, Éric Delabesse, Elizabeth Macintyre, Yves Chalandon, Norbert Ifrah, Hervé Dombret - Journal of Clinical Oncology 2018 被引用: 151

  17. Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel

    著者: Nicola Gökbuget, Nicolas Boissel, Sabina Chiaretti, Hervé Dombret, Michael Doubek, Adele K. Fielding, Robin Foà, Sebastian Giebel, Dieter Hoelzer, Mathilde Hunault, David I. Marks, Giovanni Martinelli, Oliver G. Ottmann, Anita W. Rijneveld, Philippe Rousselot, Josep‐María Ribera, Renato Bassan - Blood 2024 被引用: 76

  18. Management of ALL in adults: 2024 ELN recommendations from a European expert panel

    著者: Nicola Gökbuget, Nicolas Boissel, Sabina Chiaretti, Hervé Dombret, Michael Doubek, Adele K. Fielding, Robin Foà, Sebastian Giebel, Dieter Hoelzer, Mathilde Hunault, David I. Marks, Giovanni Martinelli, Oliver G. Ottmann, Anita W. Rijneveld, Philippe Rousselot, Josep‐María Ribera, Renato Bassan - Blood 2024 被引用: 109

  19. BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia

    著者: Matthew S. Zabriskie, Christopher A. Eide, Srinivas K. Tantravahi, Nadeem A. Vellore, Johanna Estrada, Franck E. Nicolini, H. Jean Khoury, Richard A. Larson, Marina Konopleva, Jörge E. Cortes, Hagop M. Kantarjian, Elias Jabbour, Steven M. Kornblau, Jeffrey H. Lipton, Delphine Réa, Leif Stenke, Gisela Barbany, Thoralf Lange, Juan Carlos Hernández‐Boluda, Gert J. Ossenkoppele, Richard D. Press, Charles Chuah, Stuart L. Goldberg, Meir Wetzler, François-Xavier Mahon, Gabriel Étienne, Michele Baccarani, Simona Soverini, Gianantonio Rosti, Philippe Rousselot, Ran Friedman, Marie Deininger, Kimberly R. Reynolds, William L. Heaton, Anna M. Eiring, Anthony D. Pomicter, Jamshid S. Khorashad, Todd W. Kelley, Riccardo Baron, Brian Druker, Michael W. Deininger, Thomas O’Hare - Cancer Cell 2014 被引用: 366

  20. Novel precision medicine approaches and treatment strategies in hematological malignancies

    著者: Richard Rosenquist, Elsa Bernard, Tom Erkers, David W. Scott, Raphaël Itzykson, Philippe Rousselot, Jean Soulier, Martin Hutchings, Päivi Östling, Lucia Cavelier, Thoas Fioretos, Karin E. Smedby - Journal of Internal Medicine 2023 被引用: 45

  21. Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease

    著者: Philippe Rousselot, Aude Charbonnier, Pascale Cony‐Makhoul, Philippe Agapé, Franck E. Nicolini, Bruno Varet, Martine Gardembas, Gabriel Étienne, Delphine Réa, Lydia Roy, Martine Escoffre‐Barbe, Agnès Guerci‐Bresler, Michel Tulliez, Stéphane Prost, Marc Spentchian, Jean Michel Cayuela, Josy Reiffers, Jean‐Claude Chomel, Ali G. Turhan, Joëlle Guilhot, François Guilhot, François‐Xavier Mahon - Journal of Clinical Oncology 2013 被引用: 409

  22. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study

    著者: Delphine Réa, Franck E. Nicolini, Michel Tulliez, François Guilhot, Joëlle Guilhot, Agnès Guerci‐Bresler, Martine Gardembas, Valérie Coiteux, Gaëlle Guillerm, Laurence Legros, Gabriel Étienne, Jean‐Michel Pignon, Bruno Villemagne, Martine Escoffre‐Barbe, Jean‐Christophe Ianotto, Aude Charbonnier, Hyacinthe Johnson‐Ansah, Marie‐Pierre Noël, Philippe Rousselot, François‐Xavier Mahon, for the France Intergroupe des Leucémies Myéloïdes Chroniques - Blood 2016 被引用: 317

  23. Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements

    著者: Ilaria Tanasi, Ibrahima Ba, Nicolas Sirvent, Thorsten Braun, Wendy Cuccuini, Paola Ballerini, Nicolas Duployez, Aline Schmidt, Jérôme Tamburini, Sébastien Maury, Éric Doré, Chantal Himberlin, Cédric Duclos, Patrice Chevallier, Philippe Rousselot, Massimiliano Bonifacio, Hélène Cavé, André Baruchel, Hervé Dombret, Jean Soulier, Judith Landman‐Parker, Nicolas Boissel, Emmanuelle Clappier - Blood 2019 被引用: 133

  24. Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia

    著者: Hagop M. Kantarjian, Elias Jabbour, Michael W. Deininger, Elisabetta Abruzzese, Jane F. Apperley, Jörge E. Cortes, Charles Chuah, Daniel J. DeAngelo, John F. DiPersio, Andreas Hochhaus, Jeffrey H. Lipton, Franck E. Nicolini, Javier Pinilla‐Ibarz, Delphine Réa, Gianantonio Rosti, Philippe Rousselot, Neil P. Shah, Moshe Talpaz, Shouryadeep Srivastava, Xiaowei Ren, Michael J. Mauro - American Journal of Hematology 2022 被引用: 45